P405 Combined treatment of nonhealing wounds with bioengineered skin and mesenchymal stem cells Vincent Falanga, MD, Roger Williams Medical Center, Providence, RI, United States; Jaymie Panuncialman, MD, Roger Williams Medical Center, Providence, RI, United States; Polly Carson, Roger Williams Medical Center, Providence, RI, United States; Tatyana Yufit, MD, Roger Williams Medical Center, Providence, RI, United States Background: Systemic sclerosis (scleroderma) ulcers are difficult to treat. We have tested the safety and feasibility of topical application of autologous bone marrowederived cultured mesenchymal stem cells (MSCs) in conjunction with bioengineered skin construct (BSC). Methods: Three patients with scleroderma ulcers were treated. Following bone marrow aspiration, autologous MSCs were established and expanded in culture. Ulcers were treated with the MSC and then covered with BSC. Flow cytometry, immunohistochemistry, and functional studies were used to determine and confirm the phenotype of MSCs. Results: No safety problems surfaced with bone marrow aspiration and the application of autologous MSC to the wounds. On immunohistochemistry and flow cytometry, cultured mesenchymal progenitor cells showed the following stable surface markers characteristics: CD29 1 , CD44 1 , CD90 1 , CD105 1 , CD166 1 , and CD34 e (hematopoietic cell marker) and CD45 e (leukocyte common antigen). In vitro studies showed that the cultured cells were capable of differentiation into bone, cartilage, and adipose tissue. A fibrin spray system, which takes advantage of the polymerization of cells containing fibrinogen when mixed with thrombin, was used to deliver the cultured mesenchymal stem cells to the wound in a fine spray. The fibrin could also be delivered by dripping it over the wound. Pitting scars were also treated, to determine a possible positive effect and to ensure that no ulceration would result from the experimental treatment. Up to five applications of MSC covered with BSC were performed. The treatment resulted in dramatic wound stimulation and healing. The pitting scars also seemed to improve, and pain relief was rapid. Conclusions: We have developed novel techniques for culturing and delivering autologous bone marrowederived MSC to scleroderma ulcers. We have character- ized the phenotype of these cells both in vitro and in vivo. MSC covered with bioengineered skin may be a way to stimulate healing in scleroderma ulcers. The outcome appears promising. Commercial support: None identified. P406 Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel study Stacy Smith, MD, Therapeutics Clinical Research, San Diego, CA, United States; Christine Somogyi, RN, Allergan, Inc., Irvine, CA, United States; Frederick Beddingfield, MD, PhD, Allergan, Inc., Irvine, CA, United States; Scott Whitcup, MD, Allergan, Inc., Irvine, CA, United States; Steven Fagien, MD, Private Practice, Boca Raton, FL, United States Background: The safety and efficacy of bimatoprost 0.03% for the treatment of ocular hypertension has been well established in multiple randomized, double- masked, controlled clinical trials. In these studies, a significant proportion of patients demonstrated increased eyelash growth. Methods: A prospective, randomized, double-masked, vehicle-controlled study was conducted to assess the efficacy and safety of bimatoprost 0.03% solution applied to the eyelid compared with vehicle in increasing eyelash prominence. A total of 278 healthy adult subjects were enrolled at 16 centers in North America. Eyelash prominence was assessed using a Global Eyelash Assessment (GEA) photonumeric scale. Secondary endpoints, including eyelash length, fullness, darkness, and patient reported outcomes, were also assessed. Results: Statistically significantly increases in GEA responder rates were seen at the third study visit through the end of study including the primary endpoint (P \ .0001). Improvements from baseline in eyelash growth in length, fullness, and darkness were significantly greater in the bimatoprost group compared with the vehicle group at the primary endpoint and consistently at multiple other study visits before the primary endpoint. Subjects reported increased overall satisfaction with eyelash appearance and feelings of confidence, professionalism, and attractiveness, beginning at the third study visit (P # .005). Adverse events reported more frequently in patients receiving bimatoprost included pruritus, conjunctival hyper- emia, skin hyperpigmentation, and conjunctival hyperemia and were predominantly mild and occurred in \5% of subjects. Conclusions: Topically applied bimatoprost 0.03% solution was found to be effective in increasing eyelash prominence and in increasing growth of natural eyelashes, and was safe and well tolerated in this study population of healthy adult subjects. Commercial support: 100% sponsored by Allergan Inc. POSTER DISCUSSION SESSION 05— PSORIASIS/AUTOIMMUNE DISEASES P500 Ultraviolet B treatment of plaque-type psoriasis using light-emitting diodes: A new phototherapeutic approach Lajos Kemeny, MD, Department of Dermatology and Allergy, University of Szeged, Szeged, Csongrad, Hungary; Andrea Koreck, MD, Department of Dermatology and Allergology, University of Szeged, Szeged, Csongrad, Hungary; Zanett Csoma, MD, PhD, Department of Dermatology and Allergology, University of Szeged, Szeged, Csongrad, Hungary One of the major technological breakthroughs in the last decade is represented by the diversified medical applications of light emitting diodes (LEDs). LEDs emitting in the ultraviolet B (UVB) light spectrum might serve as a more convenient alternative for targeted delivery of phototherapy in inflammatory skin diseases, such as psoriasis. We investigated the efficacy of a new, UVB-LED phototherapeutic device in chronic plaque- type psoriasis. A prospective, right-left comparative, open study was performed to assess the efficacy of UVB-LED phototherapy in psoriasis. Twenty patients with stable plaque-type psoriasis were enrolled into the study. Symmetrical lesions located on the extremities or trunks were chosen. One lesion was treated with the study device, whereas the other lesion served as an untreated control. This UVB-LED device is a narrow-band UVB device with the peak intensity at 311 nm. The minimum erythema dose (MED) was measured on each patient at the start of treatment. In 10 patients, the treatment was started with 13 MED, and then the dose was increased between 20% and 50% compared to the previous treatment. The second 10 patients had an initial dose of 0.73 MED, increasing by 0.13 MED on each treatment session. Four treatments per week were given for up to 8 weeks or until complete clearance (whichever was first). In 10 subjects, a skin biopsy was taken before the study and at the end of the treatment period. Routine histology (hemtoxylineeosin stain) and immunohistochem- istry for detection of CD3 1 T cells was performed. Patients in both groups responded rapidly to the UVB-LED therapy; complete clinical clearing of the lesions was achieved in majority of the patients. Early disease resolution was observed in 11 (seven in the first group and four in the second group) patients. Clearance of psoriatic lesions was also confirmed by histology. No severe side effects occurred. At the 1 month follow-up visit, the majority of the patients had no recurrent disease. These results suggest that this innovative UVB-LED device is effective in the treatment of localized psoriasis and may be useful in other UV-responsive skin diseases. UVB-LED devices may also represent an alternative for home-based phototherapy. Commercial support: Allux Medical Inc. P501 Comorbidities associated with psoriasis in the Newfoundland and Labra- dor founder population Wayne Gulliver, NewLab Clinical Research, St. John’s, Newfoundland and Labrador, Canada; Z. Tomi, NewLab Clinical Research, St. John’s, Newfoundland and Labrador, Canada; D. MacDonald, NewLab Clinical Research, St. John’s, Newfoundland and Labrador, Canada Psoriasis is a common inherited inflammatory disorder of the skin that affects 1% to 2% of the population. The relationship between psoriasis and psoriatic arthritis has been well established both clinically and genetically. Researchers have recently suggested that there may be other comorbidities linked to psoriasis, such as obesity, type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease, and premature death. Using the Newfoundland and Labrador founder population, through the Newfoundland and Labrador Centre for Health Information, we have undertaken the task to study 3226 psoriasis patients with respect to comorbidity and the age of death. Comorbidities and age of death were also linked to the genetic marker HLA-Cw6. Data sources include NewLab psoriasis clinical database, clinical database management system (in-patient visits), and fee-for-service physician claims database (outpatient services) over an 11- year period from 1995/1996 to 2005/2006. Of the 3226 psoriasis patients, 1494 (46.3%) were identified as having at least one acute care hospitalization during the study period. Forty-six percent had at least one comorbidity; 21% had two comorbidities; and 12% had three comorbidities. Mean age (6SD) for the first acute care hospitalization was 45.0 years (618 yrs). Digestive and circulatory diseases were the leading comorbidities among hospitalized patients (27.4% and 25.8% respectively). Patients with psoriasis experienced onset before the age of 25 years; the mean age of the first hospitalization was 33.7 years (615.1; P\.001). Patients with age of onset[25 years were significantly more likely to have cardiovascular disease, genitourinary disease, respiratory disease, and neoplasm. Patients who are HLA-Cw6 positive are more likely to have neoplasm. With respect to outpatient utilization, 52% had seen a general internist, 47.1% a cardiologist, and 93.4% intervention by a diagnostic radiologist. With respect to mortality data on 202 patients, we also noted significantly decreased longevity (67.5 yrs for males; 73.0 yrs for females). There was no difference in longevity between mild and moderate to severe patients. When the age of onset of psoriasis was before the age of 25, there was significant decrease in longevity, a mean age of 59.3 versus 71.2 in patients whose age of onset was[25 years, compared to 80.0 years for the general population of Canada. Patients whose psoriasis began before the age of 25 were more likely to die of injury or poisoning, while when having an age of onset [25 years, cardiovascular disease was the more likely cause of death. Moderate to severe psoriasis patients were more likely to die of cardiovascular disease. Patients who were HLA-Cw6 positive were more likely to die of cardiovascular disease, injury, or poisoning. Overall, with respect to mortality, the mean age of death for females was 73.0 (Canadian average, 82.5 yrs) and for men was 67.5 (Canadian average, 77.4 yrs). This study demonstrated the use of the Newfoundland and Labrador founder population and the comprehensive health information databank is a powerful tool in understanding the burden of this disease that significantly impacts the psoriasis patient. These data confirm that psoriasis patients have significant comorbidities and these are often multiple, resulting in significant impacts on quality of life, health care utilization, and patients’ longevity. Commercial support: None identified. AB8 JAM ACAD DERMATOL MARCH 2009